Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric RRMS before-and-after switch study of alemtuzumab
NL-OMON49585Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alemtuzumab in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoint: Number of new or enlarging T2 lesions on brain MRI. Planned start Dec 2024; status: withdrawn.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON49585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49585.